Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind placebo-controlled study of CR8020 and CR6261 in hospitalized patients with influenza A infection
2013-003341-41Phase 2Terminated
- Sponsor
- Crucell
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Influenza A infection comparing CR8020, CR6261 and Placebo (3 arms). Primary endpoint: Rate of decline in viral load. Started Oct 2013; status: terminated.
02
Drugs
CR8020diridavumab
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2013-003341-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003341-41.